- Font:
- +
- -
(Reuters) - Transcept Pharmaceuticals Inc said a mid-stage trial of its experimental drug for obsessive compulsive disorder did not meet the main goal of showing improvements in treating symptoms better than a placebo.
The company expects to complete the remaining analyses in early 2013 and will decide on the future development of the drug, TO-2061, after further review of the data.
The trial was testing the drug in patients with obsessive compulsive disorder who had not adequately responded to treatment with approved first-line therapies.
(Reporting by Esha Dey in Bangalore; Editing by Don Sebastian)
(c) Copyright Thomson Reuters 2012. Check for restrictions at: http://about.reuters.com/fulllegal.asp
“ ”